{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:07:18Z","timestamp":1790179638119,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jgar.2026.06.013","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T06:58:39Z","timestamp":1782284319000},"page":"114-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["In vitro activity of cefiderocol against clinically relevant Gram-negative bacilli collected in China in 2023"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0417-158X","authenticated-orcid":false,"given":"Dandan","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kohira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1073-4673","authenticated-orcid":false,"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4493-0619","authenticated-orcid":false,"given":"Fupin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10459","key":"10.1016\/j.jgar.2026.06.013_bib0001","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050","volume":"404","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jgar.2026.06.013_bib0002","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s10096-025-05080-1","article-title":"In vitro activity and resistance mechanisms of novel antimicrobial agents against metallo-\u03b2-lactamase producers","volume":"44","author":"Boattini","year":"2025","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.jgar.2026.06.013_bib0003","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01726-20","volume":"65","author":"Yang","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.jgar.2026.06.013_bib0004","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01854-22","article-title":"In vitro activity of new \u03b2-lactam-\u03b2-lactamase inhibitor combinations and comparators against clinical isolates of Gram-negative bacilli: results from the China Antimicrobial Surveillance Network (CHINET) in 2019","volume":"10","author":"Guo","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"2","key":"10.1016\/j.jgar.2026.06.013_bib0005","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlae052","article-title":"Antimicrobial resistance of clinical bacterial isolates in China: current status and trends","volume":"6","author":"Qin","year":"2024","journal-title":"JAC Antimicrob Resist"},{"issue":"4","key":"10.1016\/j.jgar.2026.06.013_bib0006","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00008-23","article-title":"Klebsiella pneumoniae carbapenemase variants: the new threat to global public health","volume":"36","author":"Ding","year":"2023","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"10.1016\/j.jgar.2026.06.013_bib0007","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2024.2361007","article-title":"Molecular mechanisms responsible KPC-135-mediated resistance to ceftazidime-avibactam in ST11-K47 hypervirulent Klebsiella pneumoniae","volume":"13","author":"Shi","year":"2024","journal-title":"Emerg Microbes Infect"},{"issue":"3","key":"10.1016\/j.jgar.2026.06.013_bib0008","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.04111-23","article-title":"KPC-2 allelic variants in Klebsiella pneumoniae isolates resistant to ceftazidime-avibactam from Argentina: blaKPC-80, blaKPC-81, blaKPC-96 and blaKPC-97","volume":"12","author":"Sanz","year":"2024","journal-title":"Microbiol Spectr"},{"issue":"1","key":"10.1016\/j.jgar.2026.06.013_bib0009","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12941-024-00716-0","article-title":"Molecular epidemiology of Acinetobacter baumannii during COVID-19 at a hospital in northern China","volume":"23","author":"Huang","year":"2024","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"10","key":"10.1016\/j.jgar.2026.06.013_bib0010","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01593-25","article-title":"Occurrence of KPC-71 or the presence of NDM combined with a high expression of blaSHV contributes to low-level cefiderocol resistance in carbapenem-resistant Klebsiella pneumoniae in China","volume":"13","author":"Hong","year":"2025","journal-title":"Microbiol Spectr"},{"issue":"Suppl 7","key":"10.1016\/j.jgar.2026.06.013_bib0011","doi-asserted-by":"crossref","first-page":"S529","DOI":"10.1093\/cid\/ciz825","article-title":"The role of iron and siderophores in infection, and the development of siderophore antibiotics","volume":"69","author":"Page","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"Suppl 7","key":"10.1016\/j.jgar.2026.06.013_bib0012","doi-asserted-by":"crossref","first-page":"S538","DOI":"10.1093\/cid\/ciz826","article-title":"Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin","volume":"69","author":"Sato","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jgar.2026.06.013_bib0013","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01990-21","article-title":"In vitro susceptibility of Gram-negative pathogens to cefiderocol in five consecutive annual multinational SIDERO-WT surveillance studies, 2014 to 2019","volume":"66","author":"Karlowsky","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.jgar.2026.06.013_bib0014","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1089\/mdr.2022.0279","article-title":"In vitro activity of cefiderocol against meropenem-nonsusceptible Gram-negative bacilli with defined \u03b2-lactamase carriage: SIDERO-WT surveillance studies, 2014-2019","volume":"29","author":"Wise","year":"2023","journal-title":"Microb Drug Resist"},{"issue":"2","key":"10.1016\/j.jgar.2026.06.013_bib0015","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02712-21","article-title":"In vitro activity of cefiderocol against U.S. and European Gram-negative clinical isolates collected in 2020 as part of the SENTRY antimicrobial surveillance program","volume":"10","author":"Shortridge","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"8","key":"10.1016\/j.jgar.2026.06.013_bib0016","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.04181-23","article-title":"In vitro activity of cefiderocol against European enterobacterales, including isolates resistant to meropenem and recent \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"12","author":"Santerre Henriksen","year":"2024","journal-title":"Microbiol Spectr"},{"issue":"4","key":"10.1016\/j.jgar.2026.06.013_bib0017","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.03836-23","article-title":"In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"12","author":"Santerre Henriksen","year":"2024","journal-title":"Microbiol Spectr"},{"issue":"11","key":"10.1016\/j.jgar.2026.06.013_bib0018","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01474-24","volume":"12","author":"Kimbrough","year":"2024","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jgar.2026.06.013_bib0019","series-title":"CLSI supplement M100","article-title":"Performance Standards for antimicrobial susceptibility testing","year":"2025"},{"issue":"9","key":"10.1016\/j.jgar.2026.06.013_bib0020","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.00471-25","article-title":"The impact of commercially available media on cefiderocol susceptibility testing by broth microdilution method","volume":"63","author":"DeJonge","year":"2025","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2026.06.013_bib0021","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jgar.2023.12.007","article-title":"Rectal culture could predict carbapenem-resistant organism bloodstream infection and reduce the mortality in haematological patients: a retrospective cohort study","volume":"36","author":"Gao","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"10.1016\/j.jgar.2026.06.013_bib0022","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12941-025-00827-2","article-title":"Resistance profile and influence factors of carbapenem-resistant Klebsiella pneumoniae (CRKP) causing infections in China: a systematic review and meta-analysis","volume":"24","author":"Yang","year":"2025","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"9","key":"10.1016\/j.jgar.2026.06.013_bib0023","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3390\/antibiotics14090863","article-title":"A comparative study of ceftazidime-avibactam and meropenem-based regimens in the treatment of carbapenem-resistant Gram-negative bacterial infections in intensive care units","volume":"14","author":"Ayd\u0131n","year":"2025","journal-title":"Antibiotics (Basel)"},{"issue":"12","key":"10.1016\/j.jgar.2026.06.013_bib0024","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1017\/ice.2025.10315","article-title":"Mortality impact of carbapenem-resistant Acinetobacter baumannii (CRAB) colonization and infection: a retrospective cohort study","volume":"46","author":"Cohen","year":"2025","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"4","key":"10.1016\/j.jgar.2026.06.013_bib0025","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlaf134","article-title":"The global epidemiology of carbapenem-resistant Acinetobacter baumannii","volume":"7","author":"Boutzoukas","year":"2025","journal-title":"JAC Antimicrob Resist"},{"issue":"11","key":"10.1016\/j.jgar.2026.06.013_bib0026","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02079-25","volume":"13","author":"Kimbrough","year":"2025","journal-title":"Microbiol Spectr"},{"issue":"Suppl 1","key":"10.1016\/j.jgar.2026.06.013_bib0027","doi-asserted-by":"crossref","first-page":"63","DOI":"10.37201\/req\/s01.10.2025","article-title":"Garc\u00eda-Plaza S. Therapeutic approach in the critically ill patient with suspected multidrug resistance","volume":"38","author":"Soriano-Cuesta","year":"2025","journal-title":"Rev Esp Quimioter"},{"issue":"1","key":"10.1016\/j.jgar.2026.06.013_bib0028","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"issue":"12","key":"10.1016\/j.jgar.2026.06.013_bib0029","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/cid\/ciw684","article-title":"The effectiveness and safety of high-dose colistin: prospective cohort study","volume":"63","author":"Benattar","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jgar.2026.06.013_bib0030","volume":"24","author":"Zhan","year":"2024"},{"issue":"3","key":"10.1016\/j.jgar.2026.06.013_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2025.106563","article-title":"High prevalence of cefiderocol resistance in carbapenem-resistant Escherichia coli: a warning from multicenter clinical data in China","volume":"91","author":"Lu","year":"2025","journal-title":"J Infect"},{"issue":"1","key":"10.1016\/j.jgar.2026.06.013_bib0032","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1186\/s12879-024-10133-5","article-title":"Antimicrobial susceptibility of enterobacterales causing bloodstream infection in United States medical centres: comparison of aztreonam-avibactam with beta-lactams active against carbapenem-resistant enterobacterales","volume":"24","author":"Sader","year":"2024","journal-title":"BMC Infect Dis"},{"issue":"8","key":"10.1016\/j.jgar.2026.06.013_bib0033","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1093\/jac\/dkaf161","article-title":"Aztreonam\/avibactam activity against enterobacterales from European medical centres: summary of 5\u2005years of surveillance prior to approval for clinical use (2019-2023)","volume":"80","author":"Sader","year":"2025","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.jgar.2026.06.013_bib0034","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf250","article-title":"Aztreonam-avibactam demonstrates potent activity against carbapenem-resistant enterobacterales collected from US medical centers over a 6-year period (2017-2022)","volume":"12","author":"Papp-Wallace","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2026.06.013_bib0035","doi-asserted-by":"crossref","DOI":"10.1186\/s12866-026-05160-y","article-title":"Susceptibility to novel antimicrobial agents and molecular epidemiology of carbapenem-resistant enterobacterales: a 9-year study in Central China","author":"Han","year":"2026","journal-title":"BMC Microbiol"},{"issue":"1","key":"10.1016\/j.jgar.2026.06.013_bib0036","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1186\/s12866-025-04299-4","article-title":"Surveillance and characterization of carbapenem-resistant Enterobacter cloacae complex from China, 2015-2018","volume":"25","author":"Ye","year":"2025","journal-title":"BMC Microbiol"},{"issue":"12","key":"10.1016\/j.jgar.2026.06.013_bib0037","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00780-24","article-title":"High prevalence of carbapenem-resistant Enterobacter cloacae complex in a tertiary hospital over a decade","volume":"12","author":"Cai","year":"2024","journal-title":"Microbiol Spectr"},{"issue":"1","key":"10.1016\/j.jgar.2026.06.013_bib0038","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1186\/s12866-025-04300-0","article-title":"Characterization and transmission dynamics of carbapenemase-encoding genes in carbapenem-resistant Enterobacter cloacae isolated from eight teaching hospitals in Guangdong province, China (2022-2024)","volume":"25","author":"Chen","year":"2025","journal-title":"BMC Microbiol"},{"issue":"8","key":"10.1016\/j.jgar.2026.06.013_bib0039","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00311-22","article-title":"NDM-35-producing ST167 Escherichia coli highly resistant to \u03b2-lactams including cefiderocol","volume":"66","author":"Poirel","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jgar.2026.06.013_bib0040","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s15010-025-02647-0","article-title":"NDM-5 and siderophore receptor mutations drive high-level cefiderocol resistance in Klebsiella pneumoniae: a case series","volume":"54","author":"Potter","year":"2026","journal-title":"Infection"},{"issue":"4","key":"10.1016\/j.jgar.2026.06.013_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2025.107553","article-title":"Susceptibility to new antibiotics and genetic characterisation of carbapenemase-producing enterobacterales: low activity of cefiderocol against NDM-producing isolates","volume":"66","author":"Fax\u00e9n","year":"2025","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"10.1016\/j.jgar.2026.06.013_bib0042","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00198-20","article-title":"Structural basis of reduced susceptibility to ceftazidime-avibactam and cefiderocol in Enterobacter cloacae due to AmpC R2 loop deletion","volume":"64","author":"Kawai","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.jgar.2026.06.013_bib0043","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/cid\/ciaa355","article-title":"Clinical evolution of AmpC-mediated ceftazidime-avibactam and cefiderocol resistance in Enterobacter cloacae complex following exposure to cefepime","volume":"71","author":"Shields","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.jgar.2026.06.013_bib0044","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01505-22","article-title":"Antimicrobial activity of cefiderocol against the carbapenemase-producing Enterobacter cloacae complex and characterization of reduced susceptibility associated with metallo-\u03b2-lactamase VIM-1","volume":"67","author":"Lasarte-Monterrubio","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.jgar.2026.06.013_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2025.106603","article-title":"Cefiderocol resistance surveillance needs deepening: regional stratification, expanded KPC sampling, and dynamic mechanism tracking","volume":"91","author":"Ding","year":"2025","journal-title":"J Infect"},{"issue":"3","key":"10.1016\/j.jgar.2026.06.013_bib0046","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02670-21","article-title":"Occurrence of high levels of cefiderocol resistance in carbapenem-resistant Escherichia coli before its approval in China: a report from China CRE-Network","volume":"10","author":"Wang","year":"2022","journal-title":"Microbiol Spectr"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716526000949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716526000949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:50:22Z","timestamp":1790178622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716526000949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":46,"alternative-id":["S2213716526000949"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2026.06.013","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of cefiderocol against clinically relevant Gram-negative bacilli collected in China in 2023","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2026.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}